Drug intelligence / Profile preview

UB-923

Development stage
Preclinical
Lead developer
United BioPharma
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

UB-923 is a preclinical-stage afucosylated monoclonal antibody developed by United BioPharma (UBP) that targets the CD20 antigen. CD20 is a protein expressed on the surface of B cells and is a well-validated target for the treatment of B-cell malignancies. By utilizing afucosylation technology, UB-923 is engineered to have a higher affinity for the FcγRIIIa receptor on effector cells, such as natural killer (NK) cells, thereby significantly enhancing antibody-dependent cellular cytotoxicity (ADCC) compared to non-modified anti-CD20 antibodies. The drug is being developed for the treatment of various B-cell lymphoproliferative disorders, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and follicular lymphoma.

Other names
afucosylated anti-CD20 monoclonal antibody
02

Targets

Beyond the preview

Go deeper on UB-923.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UB-923.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call